Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist

BACKGROUND: CMP-001, also known as vidutolimod, is a virus-like particle containing a TLR9 agonist that is showing promise in early clinical trials. Our group previously demonstrated that the immunostimulatory effects of CMP-001 are dependent on an anti-Qβ antibody response which results in opsoniza...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabree, Shakoora A, Voigt, Andrew P, Blackwell, Sue E, Vishwakarma, Ajaykumar, Chimenti, Michael S, Salem, Aliasger K, Weiner, George J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183212/
https://www.ncbi.nlm.nih.gov/pubmed/34083419
http://dx.doi.org/10.1136/jitc-2021-002484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183212/
https://www.ncbi.nlm.nih.gov/pubmed/34083419
http://dx.doi.org/10.1136/jitc-2021-002484

Ejemplares similares